Multidisciplinary cancer care, Cancer, Radionuclide therapy, Molecular imaging, Diagnostic procedure, SPECT, PET-CT, Nuclear medicine conventional, Oncology, Nuclear medicine, Gastrointestinal tract
B. K. GONZALEZ ALONSO1, E. S. Fajardo Ordoñez2, R. Hernandez Ramirez3, J. P. CHÁVEZ TORRES3; 1MEXICO/MX, 2Ciudad de Mexico/MX, 3MEXICO CITY/MX
In nuclear medicine,
theranostics refer to the use of molecules marked with radionuclides for diagnostic and / or therapeutic purposes. 3,4
Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms that originate from the neuroendocrine system,
the gastrointestinal and bronchial tracts,
the prevalence of these tumors is low,
survival rates of more than 5 years have now been reported.1,2
When disease is localized,
the treatment of first choice is surgery; however,
a high percentage of patients present metastatic disease at the time of diagnosis.
When surgery is not possible in advanced stages,
treatment options with chemotherapy or external radiotherapy are limited,
therapy with somatostatin analogues is indicated.
Therapy with somatostatin-like peptides labeled with radionuclides for neuroendocrine tumors (177Lu-DOTATOC) has a response rate of 20% and tumor stabilization by 60% .5,6,7,8,9
there are teragnostic drugs for the evaluation of NETs using the PET-CT with 68Ga-DOTATOC for the pretreatment assessment of the abnormal expression of somatostatin receptors.5,6,7,8,9